Skip to content. | Skip to navigation

Personal tools
Log in

Navigation

You are here: Home / About / CCIC-2015 / CCIC 2015

CCIC 2015

8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015

8e Symposium Canadien Annuel d’Immunotherapie du Cancer (2015)


May 20-22, 2015

Vancouver Marriott Pinnacle Downtown
1128 West Hastings Street
Vancouver, BC 


Below, you will find information about:

  1. Detailed Agenda: Click here for a downloadable version of the agenda
  2. Abstracts
  3. Instructions for abstracts and posters

Please note that in an effort to make this a green meeting, we will not provide printed abstract books at the meeting.

 

1. Agenda

Wednesday, May 20, 2015

17:00 - 18:30 Registration and poster set-up Pinnacle Foyer & Shaughnessy Salon
18:30 - 19:00 Banquet and opening address Pinnacle Ballrooms
19:00 - 20:00 Keynote Lecture
Chair: Dr. Brad Nelson, BC Cancer Agency

Dr. Cliona M. Rooney, Baylor College of Medicine:
Signaling through the TCR to enhance CAR-T cell therapy for cancer
Pinnacle Ballrooms
20:00 - 20:30

Speed poster session 1 (oral presentations)
Chair: Dr. Brad Nelson, BC Cancer Agency
Abstract Numbers: P2, P4, P14, P23, P24, P44, P48 and P49

Pinnacle Ballrooms
20:30 - 23:00 Opening night reception
Meet with delegates, browse sponsor exhibits and Poster Session 1: Odd numbered posters
Shaughnessy Salon
Return to top

 

Thursday, May 21, 2015

7:30 - 8:30 Breakfast Pinnacle Foyer
8:30 - 10:00 Session 1: New approaches to adoptive T cell transfer
Chair: Dr. Jonathan Bramson, McMaster University
Pinnacle Ballrooms
Dr. Renier J. Brentjens, Memorial Sloan Kettering Cancer Center:
Adoptive T cell Therapy of Cancer: CARs and Armored CARs.
Dr. Eric Tran, National Cancer Institute:
Cell transfer therapy against somatic mutations in human gastrointestinal cancers.
 Dr. Laszlo Radvanyi, Moffitt Cancer Center and Lion Biotechnologies:
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes: Realizing an Academic Dream.
10:00 - 10:30 Coffee break Pinnacle Foyer
10:30 - 11:00

Speed poster session 2 (oral presentations)
Chair: Dr. Réjean Lapointe, Université de Montréal
Abstract Numbers: P1, P9, P10, P25, P26, P31, P32 and P59

Pinnacle Ballrooms
11:00 - 12:00 Session 2: Immune modulation
Chair: Dr. Réjean Lapointe, Université de Montréal
Pinnacle Ballrooms
Dr. Andrew Weinberg, Oregon Health and Science University
Stimulating tumor immunity through the OX40 pathway.
Dr. Paul Tumeh, UCLA Jonsson Comprehensive Cancer Center
Pre-existing Immunity and Treatment Outcome with Anti-PD1 Therapy in Melanoma.
12:00 - 13:30 Lunch Pinnacle foyer and ballrooms
13:30 - 15:30 Poster session 2Even numbered posters Shaughnessy Salon
15:30 - 17:00 Session 3: Profiling the immune response to cancer
Chair: Dr. Brad Nelson, BC Cancer Agency
Pinnacle Ballrooms
Dr. Wolf Fridman, INSERM:
Cancer subtypes and their immune microenvironments.
Dr. Sohrab Shah, BC Cancer Agency:
**How does the immune system contend with intratumoral heterogeneity?
Dr. Harlan Robins, Fred Hutchinson Cancer Research Center:
Predicting and assessing response to immune checkpoint inhibitors.
17:00 - 18:00 Keynote Lecture
Chair: Dr. Brad Nelson, BC Cancer Agency

Dr. Philip D. Greenberg, Fred Hutchinson Cancer Research Center:
T cell engineering: Empowering T cells to eradicate tumors.
Pinnacle Ballrooms
18:00 - 19:30 Dinner Pinnacle foyer and ballrooms
Return to top


Friday, May 22, 2015

7:30 - 8:30 Breakfast Pinnacle Foyer
8:30 - 10:00 Session 4: Genomic approaches to personalized immunotherapy
Chair: Dr. Rob Holt, Genome Sciences Centre, BC Cancer Agency
Pinnacle Ballrooms
Dr. Marco Marra,  Genome Sciences Centre, BC Cancer Agency:
Personalized Oncogenomics.
Dr. Kai Wucherpfennig, Dana Farber Cancer Institute:
In vivo discovery of targets for cancer immunotherapy.  
Dr. Christian Steidl, BC Cancer Agency:
**Genomic rearrangements involving programmed death ligands.
10:00 - 10:30 Coffee break Pinnacle Foyer
10:30 - 11:00

Speed poster session 3 (oral presentations)
Chair: Dr. Pamela Ohashi, Princess Margaret Cancer Centre
Abstract Numbers: P29, P30, P34, P37, P41, P53, P54 and P60

Pinnacle Ballrooms
11:00 - 12:00 Keynote Lecture
Chair: Dr. Pamela Ohashi, Princess Margaret Cancer Centre

Dr. Ron Levy, Stanford University:
Treating the tumor and treating the host.
Pinnacle Ballrooms
12:00 - 12:15 Poster prizes Pinnacle Ballrooms
12:15 Meeting adjourns  
Return to top

**NB: Titles of talks are not final

2. Abstracts

All abstracts may be obtained by clicking on the Title of the Abstract below. Please note that there will be no printed abstract book available at the Symposium. Click here if you would like to download all the abstracts.

Speed poster presentations

  1. Wednesday, May 20, 2015, 8:00pm - 8:30pm: P2, P4, P14, P23, P24, P44, P48, P49
  2. Thursday, May 21, 2015, 10:30am - 11:00am: P1, P9, P10, P25, P26, P31, P32, P59
  3. Friday, May 22, 2015, 10:30am - 11:00am: P29, P30, P34, P37, P41, P53, P54, P60

 

Poster prizes

Friday, May 22, 2015, 12:00pm - 12:15pm

 

Abstract No. Speed Poster Session Presenting Author Title of Abstract Poster Session
 First Name Last Name Number Time
P1 2 Munehide Nakatsugawa HIGH AFFINITY ANTITUMOR HLA CLASS I-RESTRICTED TCRS THAT CAN BE STAINED WITH AN HLA/PEPTIDE MONOMER COMPLEX POSSESS BROAD CROSS-REACTIVITY 1 Wednesday May 20, 8:30pm - 11:00pm
P2 1 Sarah Crome REGULATORY INNATE LYMPHOID CELLS SUPPRESS ANTI-TUMOUR T CELLS 2 Thursday May 21, 1:30pm - 3:30pm
P3 Marcus Butler A PHASE II STUDY (NCT01883323) EVALUATING THE INFUSION OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES (TIL) AND LOW-DOSE INTERLEUKIN-2 (IL-2) THERAPY FOLLOWING NON-MYELOABLATIVE LYMPHODEPLETION USING CYCLOPHOSPHAMIDE AND FLUDARABINE IN PATIENTS WITH METASTATIC MELANOMA 1 Wednesday May 20, 8:30pm - 11:00pm
P4 1 Michael Hughes PODOCALYXIN AS A PROGNOSTIC MARKER AND TARGET FOR MONOCLONAL ANTIBODY THERAPY IN CARCINOMA 2 Thursday May 21, 1:30pm - 3:30pm
P5 Kara White Moyes RECEPTOR FOR LACTATE DEHYDROGENASE V IS A NOVEL THERAPEUTIC TARGET FOR GLIOBLASTOMA 1 Wednesday May 20, 8:30pm - 11:00pm
P6 Eric Yung MUTATION REACTIVE AUTOLOGOUS T CELLS FOR THE TREATMENT OF PANCREATIC CANCERS 2 Thursday May 21, 1:30pm - 3:30pm
P7 Andy Kokaji HUMAN REGULATORY T CELL ISOLATION IN 55 MINUTES USING EASYSEP™ RELEASABLE RAPIDSPHERES™ 1 Wednesday May 20, 8:30pm - 11:00pm
P8 Linh Nguyen RE-STIMULATED TUMOR-INFILTRATING LYMPHOCYTES AND LOW-DOSE INTERLEUKIN-2 THERAPY IN PATIENTS WITH PLATINUM RESISTANT HIGH GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (NCT01883297) 2 Thursday May 21, 1:30pm - 3:30pm
P9 2 David Kroeger TUMOR INFILTRATING PLASMA CELLS ARE ASSOCIATED WITH TERTIARY LYMPHOID STRUCTURES AND PROTECTIVE IMMUNITY IN HUMAN OVARIAN CANCER 1 Wednesday May 20, 8:30pm - 11:00pm
P10 2 Nadia Al-Banna CHARACTERIZATION OF ACTIVATED TUMOR-INFILTRATING B LYMPHOCYTES 2 Thursday May 21, 1:30pm - 3:30pm
P11 Veronique Lecault A VERSATILE HIGH-THROUGHPUT MICROFLUIDIC PLATFORM FOR ANTIBODY DISCOVERY FROM NATURAL IMMUNE REPERTOIRES 1 Wednesday May 20, 8:30pm - 11:00pm
P12 Marie-Claude Bourgeois-Daigneault IFNγ-ARMED ONCOLYTIC VIRUS FOR CANCER TREATMENT  2 Thursday May 21, 1:30pm - 3:30pm
P13 John Webb PD-1 EXPRESSION CORRELATES WITH FAVORABLE PROGNOSIS IN HIGH-GRADE SEROUS OVARIAN CANCER AND IS SELECTIVELY EXPRESSED ON INTRAEPITHELIAL (CD103+) TUMOR-INFILTRATING CD8 T CELLS 1 Wednesday May 20, 8:30pm - 11:00pm
P14 1 Spencer Martin EVALUATING THE IMMUNOGENICITY OF THE OVARIAN CANCER MUTANOME 2 Thursday May 21, 1:30pm - 3:30pm
P15 Ben Lam  RAPID EXPANSION OF FUNCTIONAL HUMAN T CELLS USING A NOVEL SERUM-FREE AND XENO-FREE CULTURE MEDIUM 1 Wednesday May 20, 8:30pm - 11:00pm
P16 Michael Mielnik DEVELOPMENT OF A CELL-BASED IL-12 CANCER IMMUNOTHERAPY USING A GENETICALLY ENGINEERED MOUSE MODEL OF BREAST CANCER 2 Thursday May 21, 1:30pm - 3:30pm
P17 Michael Mielnik CD4+ T CELL PLASTICITY ENGENDERS ROBUST IMMUNITY IN RESPONSE TO IL-12 CYTOKINE THERAPY 1 Wednesday May 20, 8:30pm - 11:00pm
P18 Agne Taraseviciute A NON-HUMAN PRIMATE MODEL OF CYTOKINE RELEASE SYNDROME (CRS): TOWARDS IMPROVED SAFETY OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 2 Thursday May 21, 1:30pm - 3:30pm
P19 Nina Maeshima RAPID ISOLATION OF HIGHLY PURE T, B, AND NK CELLS IN 8 MINUTES 1 Wednesday May 20, 8:30pm - 11:00pm
P20 Anne Monette CHITOSAN THERMOGELS FOR LOCAL T LYMPHOCYTE DELIVERY FOR CANCER IMMUNOTHERAPY 2 Thursday May 21, 1:30pm - 3:30pm
P21 Mario Fidanza TOLL-LIKE RECEPTOR LIGANDS DELAY ACUTE LYMPHOBLASTIC LEUKEMIA ONSET VIA DEPLETION OF PRE-LEUKEMIC CELLS 1 Wednesday May 20, 8:30pm - 11:00pm
P22 Luis de la Maza-Borja THE IMMUNOGENIC EFFECT OF LOCAL RADIATION THERAPY AND SURGERY IN A MURINE MODEL OF MESOTHELIOMA 2 Thursday May 21, 1:30pm - 3:30pm
P23 1 Govinda Sharma A NOVEL HIGH-THROUGHPUT SCREENING APPROACH FOR THE DETECTION OF CYTOTOXIC T-CELL RECEPTOR EPITOPES 1 Wednesday May 20, 8:30pm - 11:00pm
P24 1 Christopher Helsen T-CELL ANTIGEN COUPLER (TAC TECHNOLOGY) 2 Thursday May 21, 1:30pm - 3:30pm
P25 2 Himika Dastidar EVALUATION OF SUNITINIB AND ONCOLYTIC RHABDOVIROTHERAPY IN A MOUSE TRIPLE NEGATIVE BREAST CANCER MODEL 1 Wednesday May 20, 8:30pm - 11:00pm
P26 2 Jennifer Kalina CHIMERIC PROTEINS AS IMMUNE TARGETS IN PROSTATE CANCER 2 Thursday May 21, 1:30pm - 3:30pm
P27 Matthew Wu HMGB-1 RELEASE AND THE CD8 T CELL RESPONSE ELICITED BY RADIATION TREATMENT IN MALIGNANT PLEURAL MESOTHELIOMA 1 Wednesday May 20, 8:30pm - 11:00pm
P28 David Mullins SITE-SPECIFIC IMMUNOMODULATORS (SSIs): A NOVEL IMMUNOTHERAPY FOR CANCER 2 Thursday May 21, 1:30pm - 3:30pm
P29 3 David Neilson TUMOUR ASSOCIATED T CELLS FROM HIGH-GRADE SEROUS OVARIAN CARCINOMA PATIENTS RECOGNIZE THE CANCER TESTIS ANTIGEN LACTATE DEHYDROGENASE C 1 Wednesday May 20, 8:30pm - 11:00pm
P30 3 Nicole Little AN EXPERIMENTAL APPROACH TO DISTINGUISHING THE PREDOMINANT MECHANISMS OF IMMUNE EVASION IN HIGH-GRADE SEROUS OVARIAN CANCER 2 Thursday May 21, 1:30pm - 3:30pm
P31 2 Zhi-Qiang Wang SYNERGISTIC EFFECTS OF OSM AND TNFα ON ESTROGEN RECEPTOR EXPRESSION IN BREAST CANCER  1 Wednesday May 20, 8:30pm - 11:00pm
P32 2 Marjorie Besancon THERAPEUTIC EFFECT OF PD-1 BLOCKADE IN THE MBT-2 MURINE BLADDER CANCER MODEL 2 Thursday May 21, 1:30pm - 3:30pm
P33 Denise St-Onge PROGNOSTIC VALUE OF CD1α TUMOR-INFILTRATING DENDRITIC CELLS IN NON-MUSCLE INVASIVE BLADDER CANCER 1 Wednesday May 20, 8:30pm - 11:00pm
P34 3 Lindsay DeVorkin INVESTIGATING THE ROLE OF AUTOPHAGY IN THE BREAST TUMOUR MICROENVIRONMENT AND ITS IMPLICATIONS IN ANTI-TUMOUR IMMUNITY  2 Thursday May 21, 1:30pm - 3:30pm
P35 David Mullins MELANOMA INDUCES, AND ADENOSINE SUPPRESSES, CXCR3-COGNATE CHEMOKINE PRODUCTION AND T CELL INFILTRATION OF LUNGS BEARING METASTATIC-LIKE DISEASE 1 Wednesday May 20, 8:30pm - 11:00pm
P36 Cédric Carli PERSONALIZED CANCER IMMUNOTHERAPY THROUGH MINOR HISTOCOMPATIBILITY ANTIGEN TARGETING 2 Thursday May 21, 1:30pm - 3:30pm
P37 3 Joanne Hammill T CELLS ENGINEERED WITH CHIMERIC ANTIGEN RECEPTORS TARGETING NKG2D LIGANDS DISPLAY LETHAL TOXICITY IN MICE 1 Wednesday May 20, 8:30pm - 11:00pm
P38 Scott Brown DECODING THE T CELL RESPONSE IN TUMOURS USING LARGE SCALE RNA-SEQ DATASETS 2 Thursday May 21, 1:30pm - 3:30pm
P39 Daniel Woodsworth A LYMPHOCYTE BASED CELL-TO-CELL THERAPEUTIC DELIVERY SYSTEM 1 Wednesday May 20, 8:30pm - 11:00pm
P40 Nick Dawson DESIGN AND OPTIMIZATION OF MASS CYTOMETRY TO MEASURE IMMUNE RECONSTITUTION POST-HEMATOPOIETIC STEM CELL TRANSPLANT 2 Thursday May 21, 1:30pm - 3:30pm
P41 3 Milica Tanic ROLE OF NOTCH SIGNALING IN ANTI-TUMOR-ASSOCIATED ANTIGEN T CELL ACTIVATION WITH ARTIFICIAL ANTIGEN PRESENTING CELLS  1 Wednesday May 20, 8:30pm - 11:00pm
P42 Galina Denisova CONSTRUCTION AND USE OF DARPIN LIBRARY FOR THE DISCOVERY OF TUMOR SPECIFIC ANTIGEN BINDER PROTEINS 2 Thursday May 21, 1:30pm - 3:30pm
P43 N/A
P44 1 Maartje Wouters PROGNOSTIC BENEFIT OF TUMOR-INFILTRATING LYMPHOCYTES IN PATIENTS WITH HIGH GRADE SEROUS OVARIAN CANCER IS DEPENDENT ON TREATMENT REGIMEN, SURGICAL OUTCOME AND T CELL DIFFERENTIATION 2 Thursday May 21, 1:30pm - 3:30pm
P45 Liz Halvorsen CCR5+ REGULATORY T CELLS INDUCED BY METASTATIC BREAST CARCINOMAS MIGRATE TOWARD A GRADIENT OF CCL8 AND ACCUMULATE IN THE PRIMARY TUMOUR AND METASTATIC LUNG TISSUE 1 Wednesday May 20, 8:30pm - 11:00pm
P46 Gabrielle Siegers GAMMA DELTA T CELLS AND NODAL IN THE BREAST TUMOUR MICROENVIRONMENT 2 Thursday May 21, 1:30pm - 3:30pm
P47 Brent Johnston COMBINED CHEMOTHERAPY AND NATURAL KILLER T CELL IMMUNOTHERAPY ENHANCES PROTECTION FROM BREAST CANCER METASTASIS 1 Wednesday May 20, 8:30pm - 11:00pm
P48 1 Laila-Aicha Hanafi EX VIVO ANALYSIS OF T CELL CLONE-SPECIFIC PERSISTENCE OF INFUSED CAR T CELLS BY HIGH-THROUGHPUT TCR SEQUENCING 2 Thursday May 21, 1:30pm - 3:30pm
P49 1 Julie Nielsen TOWARD PERSONALIZED LYMPHOMA IMMUNOTHERAPY: IDENTIFICATION OF COMMON DRIVER MUTATIONS RECOGNIZED BY PATIENT CD8+ T CELLS 1 Wednesday May 20, 8:30pm - 11:00pm
P50 Shirin Kalyan ANTI-CANCER EFFICACY IN A PRECLINICAL MODEL OF LUNG CANCER USING QBKPN SITE-SPECIFIC IMMUNOMODULATION 2 Thursday May 21, 1:30pm - 3:30pm
P51 Elliot Berinstein TRANSDUCTION OF NK-92 CELLS WITH A HIGH AFFINITY VARIANT OF THE FC RECEPTOR TO ENHANCE ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY 1 Wednesday May 20, 8:30pm - 11:00pm
P52 Robyn Oldham IMMUNOTHERAPEUTIC TARGETING OF AML WITH A NOVEL CD123 CAR 2 Thursday May 21, 1:30pm - 3:30pm
P53 3 Kwame Twumasi-Boateng B CELL RECRUITING ONCOLYTIC VIROTHERAPY (B-ROV): A NOVEL APPROACH TO INDUCE TERTIARY LYMPHOID STRUCTURES FOR ENHANCED IMMUNITY TO BREAST CANCER. 1 Wednesday May 20, 8:30pm - 11:00pm
P54 3 Aras Toker INVESTIGATING EPIGENETIC REGULATION OF T CELL EXHAUSTION 2 Thursday May 21, 1:30pm - 3:30pm
P55 Ingrid Elisia DMSO REPRESSES INFLAMMATORY CYTOKINE PRODUCTION FROM HUMAN BLOOD CELLS AND REDUCES AUTOIMMUNE ARTHRITIS 1 Wednesday May 20, 8:30pm - 11:00pm
P56 Frank Fan NOVEL PD-1 BLOCKADE BIOASSAY TO ASSESS THERAPEUTIC ANTIBODIES IN PD-1 AND PD-L1 IMMUNOTHERAPY PROGRAMS 2 Thursday May 21, 1:30pm - 3:30pm
P57 Sumin Jo TOLL-LIKE RECEPTOR-BASED THERAPY FOR CHILDHOOD ACUTE LEUKEMIA 1 Wednesday May 20, 8:30pm - 11:00pm
P58 Roxanne Charlebois COMBINING AN ANTI-HER2 MAB WITH TLR-3 AND -9 AGONISTS 2 Thursday May 21, 1:30pm - 3:30pm
P59 2 Jeanette Boudreau DONOR KIR3DL1 AND HLA-B SUBTYPE COMBINATIONS PREDICT ACUTE MYELOGENOUS LEUKEMIA CONTROL AFTER HLA-COMPATIBLE HEMATOPOIETIC STEM CELL TRANSPLANTATION 1 Wednesday May 20, 8:30pm - 11:00pm
P60 3 Iryna  Saranchova INTERLEUKIN-33 AND INNATE LYMPHOCYTES ARE IMMUNE DEFENSE PROGNOSTICATORS IN RECURRENT CANCER  2 Thursday May 21, 1:30pm - 3:30pm
P61 Ann Sun WORKFLOW SOLUTIONS FOR HUMAN T CELL ISOLATION AND EXPANSION: EASYSEP™ T CELL ISOLATION WITH RELEASABLE RAPIDSPHERES™ AND IMMUNOCULT™ T CELL ACTIVATION AND EXPANSION SUPPLEMENT 1 Wednesday May 20, 8:30pm - 11:00pm
Return to top

 

3. Instructions for abstracts and posters

 

  • ABSTRACT SUBMISSION IS NOW CLOSED.
  • Extended abstract submission deadline: April 10, 2015
  • Deadline for Abstract Submission: March 20, 2015, 5pm EST

 

Abstract Review Process

All abstracts will be reviewed by the CCIC Planning Committee. The Committee will evaluate appropriateness and completeness of the information as well as scientific merit. All submissions will be acknowledged and assigned an abstract number. All abstract rejections made by the Committee will be final.

Regulations and Procedures for Abstract Submission

  1. All abstract submissions must be made by the authors of the abstract.
  2. Authors may submit more than one abstract.
  3. Presenting authors must be paid Conference registrants.
  4. Abstracts must be 300 words or less. Scientific characters are acceptable. Diagrams and graphs will not be accepted.
  5. All approved abstracts will be presented as posters during the CCIC poster session.
  6. The official language of the Conference is English. Translation services will not be provided.


Poster Preparation Information
The dimensions of your poster SHOULD NOT exceed 4’ (w) by 4’ (h). Velcro dots or push pins will be provided.

If you have any questions, email or  

Return to top

Page last modified May 28, 2015